#126545
#126546
Re: Farmas USA
Offtopic, prometo final 😁
Y hoy veo la noticia (vaya timming en eco del Mundo, para suscribirse, tenían el churro hecho y había que venderlo):
https://www.elmundo.es/economia/macroeconomia/2021/01/08/5ff7284f21efa056438b4593.html
Se va! Se va! A 40k$!!
Me lo quitan de las manos. Esto como todas las burbujas de la historia.. Triunfa el que vende a tiempo y fracasa el que compra el ultimo.
Con la trampa además (sin entrar en el valor de las criptos) es que es una replica. Hecha con datos de una subempresa, Lukka..
Que además ya valora BTC como el 2º Banco del mundo...
Y luego como tsla, subir subir subir..
Y hoy veo la noticia (vaya timming en eco del Mundo, para suscribirse, tenían el churro hecho y había que venderlo):
https://www.elmundo.es/economia/macroeconomia/2021/01/08/5ff7284f21efa056438b4593.html
Se va! Se va! A 40k$!!
Me lo quitan de las manos. Esto como todas las burbujas de la historia.. Triunfa el que vende a tiempo y fracasa el que compra el ultimo.
Con la trampa además (sin entrar en el valor de las criptos) es que es una replica. Hecha con datos de una subempresa, Lukka..
Que además ya valora BTC como el 2º Banco del mundo...
Y luego como tsla, subir subir subir..
Solo se que no se nada.
#126547
Re: Farmas USA
#126548
Re: Farmas USA
GiLD
Aumenta previsión de resultados. Veo la vela mensual y semanal y me dice: ¡saltaaa ya!
Edito: acepto ideas gráfica...
https://www.gilead.com/news-and-press/press-room/press-releases/2021/1/gilead-sciences-announces-updated-2020-guidance
https://www.gilead.com/news-and-press/press-room/press-releases/2021/1/gilead-sciences-announces-updated-2020-guidance
Aumenta previsión de resultados. Veo la vela mensual y semanal y me dice: ¡saltaaa ya!
Edito: acepto ideas gráfica...
https://www.gilead.com/news-and-press/press-room/press-releases/2021/1/gilead-sciences-announces-updated-2020-guidance
https://www.gilead.com/news-and-press/press-room/press-releases/2021/1/gilead-sciences-announces-updated-2020-guidance
#126549
Re: Farmas USA
KPTI
Previsión trimestral. El rojo que se ve es por desdenso de ingresos entre 4-6%. Ni caso. De hecho, supera las ventas estimadas por los analistas.
NEWTON, Mass., Jan. 11, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced preliminary unaudited fourth quarter and full year 2020 total revenue estimates including net product sales for XPOVIO, the Company's first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) medicine, and provided additional updates on XPOVIO's commercial progress. Based on preliminary unaudited financial information, Karyopharm expects total revenues for the fourth quarter of 2020 to be between $35.0 million and $36.0 million and between $108.0 million and 109.0 million for the full year of 2020. Additionally, Karyopharm expects net product sales of XPOVIO to be between $20.0 million and $20.5 million during the fourth quarter and between $76.0 million and $76.5 million for the full year 2020. Net sales for the fourth quarter were largely driven by prescription demand from both academic and community-based oncologists for patients with penta-refractory multiple myeloma. Additional sales were also generated from patients with diffuse large B-cell lymphoma (DLBCL). Finally, approximately $15 million of license revenue was also recognized in the fourth quarter following progress made toward the international expansion for XPOVIO. XPOVIO sales in the fourth quarter of 2020 were approximately 4-6% lower than the third quarter of 2020. Sales were affected by the recent surge in U.S. COVID-19 cases impacting both patient visits to their healthcare providers, as well as reduced in-person access for Karyopharm's commercial team to its physician customers. Additionally, increased competition, specifically in the penta-refractory multiple myeloma setting, also contributed to the sales pressure in the quarter. Importantly, XPOVIO prescription demand was higher in December 2020 compared to either October or November 2020. On a quarterly basis, Karyopharm expects XPOVIO sales to return to growth beginning in the first quarter of 2021 as compared to the fourth quarter of 2020 following the expanded FDA approval of XPOVIO granted in late December and the related commercial launch which began immediately thereafter.
Previsión trimestral. El rojo que se ve es por desdenso de ingresos entre 4-6%. Ni caso. De hecho, supera las ventas estimadas por los analistas.
NEWTON, Mass., Jan. 11, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced preliminary unaudited fourth quarter and full year 2020 total revenue estimates including net product sales for XPOVIO, the Company's first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) medicine, and provided additional updates on XPOVIO's commercial progress. Based on preliminary unaudited financial information, Karyopharm expects total revenues for the fourth quarter of 2020 to be between $35.0 million and $36.0 million and between $108.0 million and 109.0 million for the full year of 2020. Additionally, Karyopharm expects net product sales of XPOVIO to be between $20.0 million and $20.5 million during the fourth quarter and between $76.0 million and $76.5 million for the full year 2020. Net sales for the fourth quarter were largely driven by prescription demand from both academic and community-based oncologists for patients with penta-refractory multiple myeloma. Additional sales were also generated from patients with diffuse large B-cell lymphoma (DLBCL). Finally, approximately $15 million of license revenue was also recognized in the fourth quarter following progress made toward the international expansion for XPOVIO. XPOVIO sales in the fourth quarter of 2020 were approximately 4-6% lower than the third quarter of 2020. Sales were affected by the recent surge in U.S. COVID-19 cases impacting both patient visits to their healthcare providers, as well as reduced in-person access for Karyopharm's commercial team to its physician customers. Additionally, increased competition, specifically in the penta-refractory multiple myeloma setting, also contributed to the sales pressure in the quarter. Importantly, XPOVIO prescription demand was higher in December 2020 compared to either October or November 2020. On a quarterly basis, Karyopharm expects XPOVIO sales to return to growth beginning in the first quarter of 2021 as compared to the fourth quarter of 2020 following the expanded FDA approval of XPOVIO granted in late December and the related commercial launch which began immediately thereafter.
#126550
Re: Farmas USA
#126551
Re: Farmas USA
día de palos?
lo de Twitter ha caldeado los ánimos
mucho giro MACD 1h a bearish ... tengo tiempo, a casi tope cash, no hay prisa.
por cierto, mi cambio de divisa no fue a 1,23x como dije, se me fue la cabeza, fue por los 1,22medios
edito: uy ya se ve verdecillo por ahi, :))))
lo de Twitter ha caldeado los ánimos
mucho giro MACD 1h a bearish ... tengo tiempo, a casi tope cash, no hay prisa.
por cierto, mi cambio de divisa no fue a 1,23x como dije, se me fue la cabeza, fue por los 1,22medios
edito: uy ya se ve verdecillo por ahi, :))))
#126552